Skip to main content

A Genomics ETF at the Center of the Coronavirus Fight

In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM), which is higher by more than 52% in the current quarter....
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.